Shanghai GenePharma Licenses Alnylam siRNA Patents

By: China Bio Today Saturday, March 22, 2008 4:46 PM

Article Author

Follow Me

Bio and Articles
Author's Website

Vote for next session

The next market session will close:

Shanghai GenePharma Co., Ltd. signed a non-exclusive worldwide license to use the Kreutzer-Limmer siRNA patents belonging to Alnylam Pharmaceuticals (NSDQ: ALNY). The license, which is the first transaction Alnylam has signed with a China biotech, covers the right to manufacture and provide RNAi research products and services. GenePharma will manufacture RNAi reagent products for research use in China and worldwide.

The Kreutzer-Limmer patent family involves aspects of the structure and uses of RNAi products, including their use to mediate RNAi in mammalian cells.

Alnylam has entered 16 license agreements for the Kreutzer-Limmer patents with research product suppliers.

Founded in 2003, Shanghai GenePharma specializes in developing and manufacturing RNA synthesis monomers, modified RNA monomers, siRNA oligos, miRNA oligos, etc. It is currently expanding into large-scale siRNA synthesis. Shanghai GenePharma also develops new chemically modified siRNA synthesis technologies, miRNA purification, detection technologies, and it has begun to supply comprehensive RNAi-related services to academic and industrial customers.

Bookmark:
Email
Print

The above story is the opinion of the author only and it does not reflect iStockAnalyst opinion. Further, the author is not personally advising you regarding the suitability of the story for your investment needs. In no event iStockAnalyst will be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from or arising out of, or in connection with the use of this information. Please consult your investment advisor before making any investment decision.

Related Stories